News
XOMA
41.95
+0.07%
0.03
Weekly Report: what happened at XOMA last week (0601-0605)?
Weekly Report · 2d ago
Weekly Report: what happened at XOMA last week (0525-0529)?
Weekly Report · 06/01 09:42
Weekly Report: what happened at XOMA last week (0518-0522)?
Weekly Report · 05/25 09:43
Xoma downgraded to Hold from Buy at Benchmark
TipRanks · 05/22 15:47
XOMA Royalty Advances Merger Plans and Governance Changes
TipRanks · 05/22 10:35
XOMA Royalty shareholders approve 2026 employee stock purchase plan with 500,000 shares
PUBT · 05/22 10:05
Can XOMA's Late-Stage Pipeline Finally Justify the Royalty Model?
Barchart · 05/18 16:03
XOMA Royalty amends merger agreement with Ligand Pharmaceuticals
TipRanks · 05/18 14:08
XOMA Royalty amends Ligand merger deal to add HoldCo as party
PUBT · 05/18 13:12
Weekly Report: what happened at XOMA last week (0511-0515)?
Weekly Report · 05/18 09:43
XOMA Q1 net income falls to $4.5 million; total income and revenues slip to $12.32 million
PUBT · 05/12 20:16
XOMA's Liquidation Pivot May Be Masking a Drying Royalty Stream
Barchart · 05/11 16:09
Weekly Report: what happened at XOMA last week (0504-0508)?
Weekly Report · 05/11 09:41
Weekly Report: what happened at XOMA last week (0427-0501)?
Weekly Report · 05/04 09:41
This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday
Benzinga · 04/30 16:15
XOMA Royalty Price Target Announced at $39.00/Share by HC Wainwright & Co.
Dow Jones · 04/30 10:50
XOMA Royalty Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 04/30 10:50
HC Wainwright & Co. Downgrades XOMA Royalty to Neutral, Announces $39 Price Target
Benzinga · 04/30 10:40
Xoma downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 04/30 10:13
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
Barchart · 04/28 11:45
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.